OakChart

OnKure Therapeutics Inc

OKURHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

3.36-0.03 (-0.74%)
2026-11-12 03:38 CET
Market cap
136.09 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-61.85 USD m
Free cash flow, TTM
-47.94 USD m
EPS diluted, TTM
-2.77
P/E
-
Compare

Price

OKUR against its 20, 50 and 200-day averages
2050200beatearnings
2.003.004.001.5M3.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OKURclose 3.3620-day 2.6150-day 2.76200-day 3.613.3652w low

37.5% under the 52-week high of 5.38 on 1 May 2026. 52-week low 2.01 on 16 Oct 2026. Last 15 sessions, 57.5% high to low

Volume 0.68× normal · the line is the 50-bar volume average

Profile

OKUR
52-week range, 40% of the way up
2.015.38

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

IndexRUT
Employees45
IPOApr 09, 2021
Beta0.15
ATR, 14d0.26
Rel volume0.68
Short float4.66%
Insider own31.26%
Inst own71.86%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap136.09M
Enterprise Value-26.43M
Income-61.85M
Sales0.00M
Book/sh3.89
Cash/sh4.03
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees45
IPOApr 09, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.86
P/C0.83
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio18.84
Current Ratio18.84
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.77
EPS next Y-1.63
EPS next Q-0.46
EPS this Y57.42%
EPS next Y13.17%
EPS next 5Y30.38%
EPS past 3/5Y40.79% 11.29%
Sales past 3/5Y- -
EPS Y/Y TTM55.14%
Sales Y/Y TTM-
EPS Q/Q67.10%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.11.48% -100.00%

Ownership

Insider Own31.26%
Insider Trans-0.01%
Inst Own71.86%
Inst Trans12.81%
ROA-51.56%
ROE-55.18%
ROIC-39.08%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2028.77%
SMA5021.73%
SMA200-6.91%
Trades-

Technical

Shs Outstand40.50M
Shs Float27.84M
Short Float4.66%
Short Ratio4.26
Short Interest1.30M
52W High5.38 -37.55%
52W Low2.01 67.16%
Volatility14.83% 10.06%
ATR (14)0.26
RSI (14)70.99
Beta0.15
Rel Volume0.68
Avg Volume304.81K
Volume205,836

Performance

Perf Week29.73%
Perf Month43.28%
Perf Quarter-13.85%
Perf Half Y-1.18%
Perf YTD15.86%
Perf Year5.99%
Perf 3Y-94.75%
Perf 5Y-96.00%
Perf 10Y-
Recom1.50
Target Price13.33
Prev Close3.38
Price3.36
Change %-0.74%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Apr 30, 2025InitiatedEEvercore ISIOutperform
Dec 05, 2024InitiatedLLeerink PartnersOutperform$33+882.1%
Oct 10, 2024InitiatedOOppenheimerOutperform$35+941.7%
Dec 15, 2023DowngradeLLeerink PartnersOutperform → Market Perform
Dec 15, 2023DowngradeJJefferiesBuy → Hold
Dec 15, 2023DowngradeHH.C. WainwrightBuy → Neutral$30 → $1.50-55.4%
Dec 14, 2023DowngradeWWilliam BlairOutperform → Mkt Perform
Dec 14, 2023DowngradeRRobert W. BairdOutperform → Neutral$28 → $3-10.7%
Dec 14, 2023DowngradePPiper SandlerOverweight → Neutral$25 → $4+19.0%
Dec 14, 2023DowngradeLLadenburg ThalmannBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
RLAYRelay Therapeutics Inc4.36B
CELCCelcuity Inc3.16B
OLMAOlema Pharmaceuticals Inc703.48M
KZIAKazia Therapeutics Limited ADR84.92M
ARVNArvinas Inc452.51M
BDTXBlack Diamond Therapeutics Inc92.50M
PVLAPalvella Therapeutics Inc2.40B
ACRVAcrivon Therapeutics Inc67.28M
ZNTLZentalis Pharmaceuticals Inc185.72M
TYRATyra Biosciences Inc1.44B

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Saccomano Nicholas APresident and CEOSep 21 '26Sale2.978725911,160Sep 23 04:54 PM
Leverone Jason A.Chief Financial OfficerSep 21 '26Sale2.9730289818,500Sep 23 04:52 PM
Saccomano Nicholas APresident and CEOJun 22 '26Sale4.408637811,247Jun 24 07:29 PM
Leverone Jason A.Chief Financial OfficerJun 22 '26Sale4.403031,33218,802Jun 24 07:27 PM
Saccomano Nicholas APresident and CEOMar 23 '26Sale4.16863577,333Mar 24 06:57 PM
Leverone Jason A.Chief Financial OfficerMar 23 '26Sale4.163011,25116,000Mar 24 06:56 PM
Saccomano Nicholas APresident and CEODec 22 '25Sale2.97872587,419Dec 23 08:09 PM
Leverone Jason A.Chief Financial OfficerDec 22 '25Sale2.9730289616,301Dec 23 08:08 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
TMEDT. Rowe Price Health Care ETFAUM: 38.55M
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 198
  • OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
  • OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
  • OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
  • OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Ka Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 (GlobeNewswire)
  • OnKure Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire) -9.96%
  • OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies (GlobeNewswire) -13.07%
  • OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) +7.39%
  • OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +5.33% -6.96%
  • OnKure Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.20%
  • OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +20.00%
  • OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -11.16%
  • OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
  • OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences (GlobeNewswire) +7.45%
  • OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 (GlobeNewswire) -8.47%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.360-0.407-1.1100.000.173
2026Q22026-08-04-0.310-0.535-0.3080.000.174
2026Q12026-05-05-1.110-0.743-1.1080.000.174
2025Q42026-03-12-0.990-1.152-0.9930.000.005
2025Q32025-11-06-1.090-1.198-1.0860.000.005
2025Q22025-08-12-1.140-1.248-1.1390.000.005
2025Q12025-05-06-1.190-1.380-1.1860.000.003
2024Q42025-03-10-1.370-0.793-2.7550.000.003
2024Q32024-11-06-1.036-0.965-0.2900.00-2
2024Q22024-08-13-1.600-1.000-1.6040.000.001
2024Q12024-05-07-2.500-4.367-2.5210.000.003
2023Q42024-03-28-7.000-5.780-7.0480.000.006
2023Q32023-11-13-5.700-5.714-5.6780.000.007
2023Q22023-08-10-6.500-5.300-6.4640.000.005
2023Q12023-05-11-6.000-6.040-6.0340.000.005
2022Q42023-03-27-5.600-5.884-5.5370.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-46.267--8.0150.00-
2021FY-21.900-32.333-21.9200.000.00
2022FY-21.200-21.559-21.2090.000.00
2023FY-25.200-23.724-1,1250.000.00
2024FY-15.280-2.833-3.9460.000.00
2025FY-4.400-4.560-4.4000.000.00
2026FY--1.873--0.17
2027FY--1.627--0.67
2028FY--1.485--2.00
2029FY--1.340--2.00
2030FY--1.450--2.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-053000.170.000.50
2026Q4S2026-11-043000.170.000.50
2026Q4S2026-08-053000.170.000.50
2026Q4S2026-05-063000.170.000.50
2026Q4S2026-03-133000.170.000.50
2026Q4R2026-08-05100-0.71-0.71-0.71
2026Q4R2026-07-20100-0.71-0.71-0.71
2026Q4R2026-06-21101-0.71-0.71-0.71
2026Q4R2026-05-06201-0.69-0.71-0.67
2026Q4R2026-03-13200-0.66-0.67-0.65
2026Q4E2026-11-05302-0.46-0.67-0.34
2026Q4E2026-11-04300-0.43-0.67-0.30
2026Q4E2026-10-27300-0.43-0.67-0.30
2026Q4E2026-10-25310-0.43-0.67-0.30

Estimate history

EPS, annual-5.121-8.015-21.92-21.209-1125.461-3.946-4.404-2.7666
Period2019202020212022202320242025TTM
EPS, quarterly-0.29-2.755-1.186-1.139-1.086-0.993-1.108-0.308-0.357
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.4292.4292.4462.470.03113.34713.67440.503
Period2019202020212022202320242025MRQ
Shares, quarterly12.72213.34713.44213.5313.54813.67440.39540.49640.503
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.820.830.660.560.530.050.040.03
Gross Profit-0.82-0.83-0.66-0.56-0.53-0.05-0.04-0.03
Selling, General and Administrative Excl. Other65.1762.1253.5036.3753.3239.7719.5215.44
Research and Development49.6247.8143.3431.7037.1828.1215.9113.06
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-65.99-62.95-54.16-36.93-53.85-39.82-19.55-15.47
Interest Expense0.000.000.150.000.000.00-0.00
Unusual Expense0.000.00-0.110.000.000.000.00-2.58
Net Income Before Taxes-61.85-59.52-52.67-35.31-51.95-39.77-19.46-12.44
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-61.85-59.52-52.67-35.31-51.95-39.77-19.46-12.44
Net Income From Continuing Operations-61.85-59.52-52.67-35.31-51.95-39.77-19.46-12.44
Net Income-61.85-59.52-52.67-35.31-51.95-39.77-19.46-12.44
EPS (Recurring)-1.24-4.40-3.95-1,125.46-21.21-21.92-8.01-5.86
EPS (Basic, Before Extraordinaries)-2.77-4.40-3.95-1,125.46-21.21-21.92-8.01-5.12
EPS (Diluted)-2.77-4.40-3.95-1,125.46-21.21-21.92-8.01-5.12
EBITDA-65.17-62.12-53.50-36.37-53.32-39.77-19.52-15.44
Non-Operating Income (Expense)4.143.431.521.621.890.050.090.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.3411.634.530.204.323.890.390.39
Shares Outstanding40.5013.6713.350.032.472.452.432.43
Market Capitalization136.09136.0928.7527.65----

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.230.190.200.200.200.210.210.42
Gross Profit-0.23-0.19-0.20-0.20-0.20-0.21-0.21-0.42
Selling, General and Administrative Excl. Other19.1216.7115.4113.9215.3016.1116.7936.94
Research and Development14.8812.5111.6110.6211.8112.5012.8936.94
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-19.35-16.90-15.62-14.12-15.50-16.32-17.00-37.36
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.00-
Net Income Before Taxes-17.85-15.35-15.16-13.50-14.70-15.39-15.93-35.19
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-17.85-15.35-15.16-13.50-14.70-15.39-15.93-35.19
Net Income From Continuing Operations-17.85-15.35-15.16-13.50-14.70-15.39-15.93-35.19
Net Income-17.85-15.35-15.16-13.50-14.70-15.39-15.93-35.19
EPS (Recurring)-0.36-0.31-1.11-0.99-1.09-1.14-1.19-2.76
EPS (Basic, Before Extraordinaries)-0.36-0.31-1.11-0.99-1.09-1.14-1.19-2.75
EPS (Diluted)-0.36-0.31-1.11-0.99-1.09-1.14-1.19-2.75
EBITDA-19.12-16.71-15.41-13.92-15.30-16.11-16.79-36.94
Non-Operating Income (Expense)1.501.550.460.620.800.931.07-3.41
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.493.052.783.022.962.912.751.64
Shares Outstanding40.5040.5040.4013.6713.5513.5313.4413.35
Market Capitalization136.09184.2056.6139.2937.2132.2957.7728.75

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments59.05110.7629.88101.17147.6753.6124.89
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets1.792.243.895.186.061.410.52
Total Current Assets60.84113.0033.77106.35153.7355.0225.41
Net Property, Plant & Equipment1.001.791.911.750.210.070.08
Total Investments and Advances0.000.000.000.000.000.000.00
Other Assets0.270.110.060.080.080.130.02
Total Assets62.12114.9135.73108.18154.0255.2225.50
Short Term Debt Incl. Current Port. of LT Debt0.550.540.210.400.000.000.00
Accounts Payable1.432.973.420.000.000.000.00
Other Current Liabilities3.947.033.666.726.204.582.94
Total Current Liabilities5.9210.537.297.126.204.582.94
Long Term Debt0.000.550.471.060.0092.7245.65
Provision for Risks Charges0.000.000.000.030.000.000.00
Other Liabilities0.010.000.000.000.610.040.04
Total Liabilities5.9311.087.758.216.8197.3448.63
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00129.820.000.000.000.00
Common Equity56.18103.83-101.8499.97147.21-42.12-23.13
Total Shareholders Equity56.18103.8327.9899.97147.21-42.12-23.13
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity56.18103.8327.9899.97147.21-42.12-23.13
Total Liabilities & Stockholders Equity62.12114.9135.73108.18154.0255.2225.50
Book Value Per Share4.117.78-3,245.9940.4760.20-17.34-9.52
Tangible Book Value Per Share4.117.78-3,245.9940.4760.20-17.34-9.52
Full-Time Employees45468483223-
Price to Book Ratio0.860.370.36----
Return on Assets-67.24-47.38-49.07-39.63-38.01-48.22-
Return on Equity-74.39-54.74-55.19-42.04-75.68--
Return on Invested Capital-105.93-50.46-124.12-51.43-27.02-38.46-55.21
Quick Ratio10.2810.734.6414.9324.7912.018.64
Current Ratio10.2810.734.6414.9324.7912.018.64

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-61.85-59.52-52.67-35.31-51.95-39.77-19.46-12.44
Depreciation0.820.830.660.560.530.050.040.03
Other Funds (Non Cash)12.2611.644.850.203.104.540.38-1.67
Funds from Operations-48.77-47.05-47.16-34.55-48.32-35.18-19.05-14.07
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital0.89-4.78-3.950.010.96-2.800.511.56
Cash from Operating Activities-47.89-51.83-51.12-34.55-47.36-37.98-18.54-12.51
Capital Expenditures-0.05-0.05-0.05-0.25-0.35-0.20-0.02-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-11.800.0015.930.00-57.50-23.187.40-7.23
Purchase of Investments-12.800.000.000.00-101.60-31.410.00-19.83
Sale Or Maturity of Investments1.000.0015.930.0044.108.237.4012.60
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-11.85-0.0515.87-0.25-57.84-23.387.38-7.24
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock140.850.2054.4453.120.47132.4147.2724.99
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock140.850.2054.4453.120.47132.4147.2724.99
Proceedsfrom Stock Options140.650.2054.4453.120.47132.4147.1924.96
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.0461.690.000.000.000.000.00
Other Financing Activities Uses0.00-0.04-2.040.000.000.000.000.00
Cash from Financing Activities140.850.16116.1353.120.47132.4147.2724.99
Net Change in Cash81.11-51.7180.8918.33-104.7371.0536.115.24
Free Cash Flow-47.94-51.87-51.17-34.79-47.71-38.18-18.56-12.52
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments163.31176.39192.1159.0570.3383.37
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.291.295.381.791.201.18
Total Current Assets165.59177.68197.4860.8471.5384.55
Net Property, Plant & Equipment1.071.270.811.001.211.40
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.410.400.410.270.100.12
Total Assets167.08179.35198.6962.1272.8386.07
Short Term Debt Incl. Current Port. of LT Debt0.250.340.410.550.570.56
Accounts Payable2.312.0011.021.431.292.38
Other Current Liabilities6.234.312.903.944.394.66
Total Current Liabilities8.796.6414.335.926.257.60
Long Term Debt0.540.590.000.000.120.27
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.010.010.010.010.040.04
Total Liabilities9.347.2514.345.936.417.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity157.74172.11184.3556.1866.4378.17
Total Shareholders Equity157.74172.11184.3556.1866.4378.17
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity157.74172.11184.3556.1866.4378.17
Total Liabilities & Stockholders Equity167.08179.35198.6962.1272.8386.07
Book Value Per Share3.894.254.564.114.905.78
Tangible Book Value Per Share3.894.254.564.114.905.78
Full-Time Employees---45--
Price to Book Ratio0.861.001.010.590.480.35
Return on Assets-51.56-44.24-39.35-67.24-107.93-85.20
Return on Equity-55.18-46.91-42.73-74.39-115.64-90.56
Return on Invested Capital-11.28-8.89-8.22-24.03-22.09-19.62
Quick Ratio18.8426.7513.7810.2811.4511.13
Current Ratio18.8426.7513.7810.2811.4511.13

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-17.85-15.35-15.16-13.50-14.70-15.39
Depreciation0.230.190.200.200.200.21
Other Funds (Non Cash)3.433.022.783.022.962.91
Funds from Operations-14.18-12.14-12.17-10.28-11.53-12.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.101.78-0.76-1.23-1.50-1.00
Cash from Operating Activities-13.08-10.35-12.94-11.51-13.04-13.27
Capital Expenditures-0.03-0.00-0.01-0.01-0.01-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-1.94-9.870.000.000.000.00
Purchase of Investments-2.94-9.870.000.000.000.00
Sale Or Maturity of Investments1.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.97-9.87-0.01-0.01-0.01-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.01-5.38146.000.240.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.01-5.38146.000.240.000.00
Proceedsfrom Stock Options-0.01-5.58146.000.240.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.01-5.38146.000.240.000.00
Net Change in Cash-15.06-25.60133.06-11.28-13.04-13.29
Free Cash Flow-13.11-10.36-12.94-11.52-13.04-13.29

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.66%1.3M27.8M267.77K
2026-10-154.98%1.4M27.8M232.44K
2026-09-304.40%1.2M27.8M173.76K
2026-09-154.94%1.4M27.8M252.39K
2026-08-314.75%1.3M27.8M290.93K
2026-08-143.85%1.1M27.8M298.45K
2026-07-314.06%1.2M29.2M299.71K
2026-07-154.05%1.2M29.2M303.69K
2026-06-303.01%0.9M29.2M304.72K
2026-06-150.97%0.3M29.2M337.11K
2026-05-290.81%0.2M29.2M310.46K
2026-05-152.24%0.2M8.9M295.98K
2026-04-301.01%0.1M10.2M291.96K
2026-04-150.69%0.1M10.1M286.48K
2026-03-311.91%0.2M8.6M265.01K
2026-03-130.09%0.0M8.6M115.00K
2026-02-270.67%0.1M8.1M113.58K
2026-02-130.41%0.0M8.1M115.28K
2026-01-300.18%0.0M8.1M115.70K
2026-01-150.12%0.0M8.1M132.87K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.003.900.2018.0911.000.000.895-0.0090.001
call5.000.004.600.0020.4730.000.000.929-0.0820.001
call7.500.004.600.0021.6920.000.000.926-0.0900.001
put2.500.000.050.002.5910.000.00-0.166-0.0190.001
put5.000.004.501.9019.9041.000.00-0.071-0.0820.001
put7.501.606.500.0016.3350.000.00-0.074-0.0890.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-048-KCurrent report2026-11-04SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-07SCHEDULE 13GSEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-134/A2026-08-07SEC
2026-08-138-KCurrent report2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-10SCHEDULE 13G/ASEC
2026-08-04424B5SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.16K2
2026-080000
2026-070000
2026-06001.71K2
2026-050000
2026-040000
2026-03001.61K2
2026-020000
2026-010000
2025-12001.15K2
2025-110000

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.9.90%
BVF INC/IL8.01%
ACORN CAPITAL ADVISORS, LLC7.03%
StepStone Group LP6.59%
ADAR1 Capital Management, LLC5.54%
Vivo Capital, LLC4.77%
Vestal Point Capital, LP4.52%
BlackRock, Inc.3.71%
Trails Edge Capital Partners, LP3.56%
VANGUARD CAPITAL MANAGEMENT LLC3.56%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.75%
iShares Russell 2000 ETF1.20%
VANGUARD EXTENDED MARKET INDEX FUND0.75%
Fidelity Small Cap Index Fund0.71%
iShares Russell 2000 Value ETF0.48%
VANGUARD RUSSELL 2000 INDEX FUND0.37%
Fidelity Extended Market Index Fund0.33%
iShares Micro-Cap ETF0.20%
Fidelity Total Market Index Fund0.19%
Schwab Small-Cap Index Fund0.16%

OakChart. OKUR. Cached 15 minutes.